GSK plc
NYSE:GSKDrug Manufacturers - General
-$1.34 today
- Market cap
- $97.53B
- Beta
- 0.29
- P/E (TTM)
- 13.3
- EPS (TTM)
- $1.45
- Dividend yield
- 3.48%
Volume 2.02M
Average 4.07M
GSK EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
GSK plcNYSE: GSK
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA dips below year-ago levels
Q2 FY2026 EBITDA of £760.81M fell 76.4% year over year, behind the +2.2% change in trailing-twelve-month EBITDA. Sequentially, it fell 72.6% from the prior quarter. Over 3 fiscal years it compounded at +6.5% a year.
Context
- EBITDA amounted to 31.8% of revenue in FY2025, up 10.6 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 16 analysts of £11.79B (+13.4%) for the fiscal year ending Dec 2026, a slowdown from the +56.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- £760.81M-72.6% QoQ
- Last fiscal yearDec 2025
- £10.4B+56.0% YoY
- LTMJun 2026
- £8.8B+2.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -76.4% | -0.9% | +75.5 pp |
| 1 year | +56.0% | +13.4% | -42.6 pp |
| 3-year CAGR | +6.5% | +7.6% | +1.1 pp |
| 5-year CAGR | +5.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
GBP · from the income statement
- Latest · FY2025
- 10.4B GBP
- Year-over-year change
- +56.0%
- 4-year CAGR
- +12.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.4B | +56.0% |
| FY2024 | 2024-12-31 | 6.67B | -26.6% |
| FY2023 | 2023-12-31 | 9.08B | +5.6% |
| FY2022 | 2022-12-31 | 8.6B | +32.6% |
| FY2021 | 2021-12-31 | 6.49B | — |
EBITDA vs competitors
How GSK compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +2.2% is the 6th highest of 10, against a peer median of +4.7%.
- EBITDA amounts to 26.5% of revenue for GSK, versus a peer median of 34.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 180.91B DKK | +4.7% | +26.8% | 54.9% | |
| LTM Jun 2026 | $43.3B USD | +103.7% | +54.1% | 54.4% | |
| LTM Sep 2026 | $30.81B USD | -22.1% | +15.6% | 31.0% | |
| LTM Jun 2026 | $22.26B USD | -2.0% | +16.1% | 40.0% | |
| LTM Sep 2026 | $21.37B USD | +18.6% | +29.7% | 34.4% | |
| LTM Jun 2026 | $17.62B USD | +10.8% | +11.6% | 46.2% | |
| LTM Jun 2026 | €14.77B EUR | +15.5% | -2.6% | 30.2% | |
| LTM Jun 2026 | $13.93B USD | -44.4% | +9.9% | 21.0% | |
| LTM Jun 2026 | $13.49B USD | -33.1% | -25.8% | 21.2% | |
| LTM Jun 2026 | £8.8B GBP | +2.2% | +6.5% | 26.5% | |
| Peer median (excluding GSK) | — | +4.7% | +15.6% | 34.4% | |
Competitors are the stored peer set for GSK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 24.7B | 29.32B | 30.33B | 31.38B | 32.67B |
| Cost of Revenue | 8.16B | 9.55B | 8.57B | 9.05B | 9.02B |
| Gross Profit | 16.53B | 19.77B | 21.76B | 22.33B | 23.65B |
| Gross Margin | 66.9% | 67.4% | 71.8% | 71.2% | 72.4% |
| Research & Development | 5.02B | 5.49B | 6.22B | 6.4B | 7.53B |
| Selling, General & Admin | 7.07B | 8.37B | 9.39B | 11.02B | 9.09B |
| Operating Expenses | 12.18B | 13.34B | 15.02B | 18.31B | 15.31B |
| Depreciation & Amortization | 2.12B | 2.15B | 2.29B | 2.55B | 2.31B |
| EBITDA | 6.49B | 8.6B | 9.08B | 6.67B | 10.4B |
| EBITDA Margin | 26.3% | 29.3% | 29.9% | 21.3% | 31.8% |
| Operating Income | 4.36B | 6.43B | 6.75B | 4.02B | 8.34B |
| Operating Margin | 17.6% | 21.9% | 22.2% | 12.8% | 25.5% |
| Interest Income | 28M | 64.27M | 40M | 67.39M | 56M |
| Interest Expense | 784M | 855.53M | 775M | 657.58M | 687M |
| Other Income / Expenses | (758M) | (805M) | (681M) | (544M) | (937M) |
| Income Before Tax | 3.6B | 5.63B | 6.06B | 3.48B | 7.4B |
| Pre-Tax Margin | 14.6% | 19.2% | 20.0% | 11.1% | 22.7% |
| Income Tax Expense | 83M | 707M | 756M | 526M | 1.11B |
| Net Income | 4.39B | 14.96B | 4.93B | 2.58B | 5.72B |
| Net Margin | 17.8% | 51.0% | 16.2% | 8.2% | 17.5% |
| EPS (Basic) | 2.74 | 7.44 | 2.44 | 1.26 | 2.82 |
| EPS (Diluted) | 2.70 | 7.32 | 2.40 | 1.24 | 2.78 |
| Weighted Avg Shares | 1.6B | 2.01B | 2.03B | 2.04B | 2.03B |
| Weighted Avg Shares (Diluted) | 1.62B | 2.04B | 2.06B | 2.07B | 2.06B |
GSK plc
NYSE:GSK
Intrinsic Alpha fair value
Locked
Current Price
$48.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.